Malin to sell off stakes in two medical supply companies

Xenex and Altan have seen demand for products climb due to Covid-19

29th March, 2020
Malin to sell off stakes in two medical supply companies
Darragh Lyons Chief executive, Malin. Picture: Fergal Phillips

Malin, the biotech investment firm, will look to dispose of its stakes in non-core companies that are recording a surge in demand for their products as a result of the Covid-19 outbreak.

Darragh Lyons, Malin’s chief executive, said its stakes in Altan and Xenex would be attractive to buyers in the next year as both companies had recorded growth in revenues as hospitals stocked up on supplies. Xenex makes a robot that disinfects hospitals, while...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

How to manage: Supreme Court decision to have significant impact on workplace dispute cases

How to manage: Diversity is about more than padding a board with people who look different

Kerry Group’s steady results signal global bounceback

The sale of the century: what next for Arnotts and BT?